ARTIVION, INC. - 8-K Filing
Artivion exercised its option to acquire Endospan for $175 million in cash, following Endospan's FDA approval of its Nexus™ product on April 2, 2026. The acquisition is expected to be funded through borrowings under Artivion's term loan facility, with a net purchase price of approximately $135 million after offsetting existing loans. The company also reported first-quarter 2026 financial results, though specific revenue and EPS figures were not disclosed in the filing. (Items: 1.01 Entry into a Material Definitive Agreement, 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $AORT